IL2RA and Epstein-Barr virus infection: The levels of soluble IL-2R were increased 1.5–2.5-fold following AM treatment; however levels are lower than those seen in patients with chronic hepatitis infection (1.6–4-fold), acute EBV infections (7-fold), or B-cell cancer patients (up to 6.4-fold) but are similar to levels seen in autoimmune patients with rheumatoid arthritis (2-fold) [43–46].